Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review

European Journal of Neurology

Volumn 22, Issue 9, 2015, Pages 1249-1259

  Dersch, R ^a   Freitag, M H ^b   Schmidt, S ^a,c   Sommer, H ^a   Rauer, S ^a   Meerpohl, J J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF OLDENBURG   (Germany)

^c UroEvidence der DGU Deutsche Gesellschaft für Urologie e V   (Germany)

Author keywords

Decision making; Drug treatment; Lyme disease; Lyme neuroborreliosis; Meta analysis; Non randomized studies; Randomized controlled trials; Systematic review

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; DOXYCYCLINE; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC THERAPY; ARTICLE; CHOLECYSTITIS; COLITIS; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DUODENUM ULCER; FATIGUE; FOLLOW UP; HUMAN; LYME DISEASE; META ANALYSIS (TOPIC); NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PLEOCYTOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHOCK; STOMATITIS; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; TREATMENT DURATION; VERTIGO; FEMALE; LYME NEUROBORRELIOSIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFOTAXIME; DOXYCYCLINE; FEMALE; HUMANS; LYME NEUROBORRELIOSIS; PENICILLINS;

EID: 84939466939     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12744     Document Type: Article

References (37)

1. Mygland A, Ljostad U, Fingerle V, et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010; 17: 8-16, e1-4.
2. Kaiser R. Neuroborreliosis. J Neurol 1998; 245: 247-255.
3. Halperin JJ, Logigian EL, Finkel MF, Pearl RA. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996; 46: 619-627.
4. Auwaerter PG, Bakken JS, Dattwyler RJ, et al. Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect Dis 2011; 11: 713-719.
5. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1089-1134.
6. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 69: 91-102.
7. Cameron D, Gaito A, Harris N, et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2004; 2(1 Suppl.): S1-S13.
8. Reeves B, Higgins J, Ramsay C, Shea B, Tugwellf P, Wellsg G. An introduction to methodological issues when including non-randomised studies in systematic reviews on the effects of interventions. Res Synth Methods 2013; 4: 11.
9. Mygland Å, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010; 17: 8-16.
10. Dersch R, Freitag MH, Schmidt S, et al. Efficacy and safety of pharmacological treatments for neuroborreliosis - protocol for a systematic review. Syst Rev 2014; 3: 117.
11. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org (accessed 31/05/2015).
12. Sterne J, Higgins J, Reeves B, on behalf of the development group for ACROBAT-NRSI. A Cochrane risk of bias assessment tool: for non-randomized studies of interventions (ACROBAT NRSI), version 1.0.0. 2014. http://www.riskofbias.info (accessed 19/12/2014).
13. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 23/1/2015).
14. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-406.
15. Ljostad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 2008; 7: 690-695.
16. Oksi J, Nikoskelainen J, Viljanen MK. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. Eur J Clin Microbiol Infect Dis 1998; 17: 715-719.
17. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994; 44: 1203-1207.
18. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991; 163: 311-318.
19. Hassler D, Zöller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime versus penicillin in the late stage of Lyme disease - prospective, randomized therapeutic study. Infection 1990; 18: 16-20.
20. Kohlhepp W, Oschmann P, Mertens HG. Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G. J Neurol 1989; 236: 464-469.
21. Pfister HW, Preac-Mursic V, Wilske B, Einhaupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol 1989; 46: 1190-1194.
22. Pfister HW, Einhäupl KM, Franz P, Garner C. Corticosteroids for radicular pain in Bannwarth's syndrome: a double-blind, randomized, placebo-controlled trial. Ann N Y Acad Sci 1988; 539: 485-487.
23. Borg R, Dotevall L, Hagberg L, et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 2005; 37: 449-454.
24. Berglund J, Stjernberg L, Ornstein K, Tykesson-Joelsson K, Walter H. 5-y follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002; 34: 421-425.
25. Elamin M, Monaghan T, Mulllins G, et al. The clinical spectrum of Lyme neuroborreliosis. Ir Med J 2010; 103: 46-49.
26. Kruger H, Kohlhepp W, Konig S. Follow-up of antibiotically treated and untreated neuroborreliosis. Acta Neurol Scand 1990; 82: 59-67.
27. Viader F, Poncelet AM, Chapon F, et al. [Neurologic forms of Lyme disease. 12 cases]. Rev Neurol (Paris) 1989; 145: 362-368.
28. Bateman DE, Lawton NF, White JE, Greenwood RJ, Wright DJ. The neurological complications of Borrelia burgdorferi in the New Forest area of Hampshire. J Neurol Neurosurg Psychiatry 1988; 51: 699-703.
29. Hirsch E, Sellal F, Christmann D, et al. [Meningoradiculitis after a tick bite. Study of 31 cases]. Rev Neurol (Paris) 1987; 143: 182-188.
30. Libá-Vrabelová Z, Kayserová J, Komárek V. Časty výskyt lymeské neuroboreliózy u dětí v České Republice [Frequent incidence of Lyme neuroborreliosis in children in the Czech Republic]. Cesk Slov Neurol N 2013; 76: 63-69.
31. Kristoferitsch W, Baumhackl U, Sluga E, Stanek G, Zeiler K. High-dose penicillin therapy in meningopolyneuritis Garin-Bujadoux-Bannwarth. Clinical and cerebrospinal fluid data. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 263: 357-364.
32. Ljostad U, Mygland A. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol 2010; 17: 118-123.
33. Eikeland R, Ljostad U, Mygland A, Herlofson K, Lohaugen GC. European neuroborreliosis: neuropsychological findings 30 months post-treatment. Eur J Neurol 2012; 19: 480-487.
34. Eikeland R, Mygland A, Herlofson K, Ljostad U. European neuroborreliosis: quality of life 30 months after treatment. Acta Neurol Scand 2011; 124: 349-354.
35. Cadavid D, Auwaerter P, Aucott J, Rumbaugh J. Treatment for the neurological complications of Lyme disease (Protocol). Cochrane Database Syst Rev 2008.
36. Bensch J, Olcen P, Hagberg L. Destructive chronic borrelia meningoencephalitis in a child untreated for 15 years. Scand J Infect Dis 1987; 19: 697-700.
37. Stanek G, Fingerle V, Hunfeld KP, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17: 69-79.